UPB · Upstream Bio
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Market Cap
152.4M
52 Wk Range
$2.68 - $33.68
Previous Close
$2.86
Open
$2.86
Volume
891,334
Day Range
$2.73 - $2.98
Enterprise Value
-54.75M
Cash
207.4M
Avg Qtr Burn
-54.23M
Insider Ownership
15.06%
Institutional Own.
92.76%
Qtr Updated
Sep 30th 2026
